SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DPII: Discovery Partners Int'l
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mopgcw who wrote (3)4/16/2002 10:28:18 PM
From: mopgcw  Read Replies (1) of 111
 
Discovery Partners, Xenon Genetics In Drug Collaboration

DOW JONES NEWSWIRES

SAN DIEGO -- Discovery Partners International Inc. (DPII) expanded its agreement to provide research services to privately held Xenon Genetics Inc.

Terms weren't disclosed.

In a press release Tuesday, Discovery Partners said under the expanded pact, it will provide the services for Xenon's work on new drug targets for metabolic syndromes including dyslipidemia, obesity and insulin resistance target.

Discovery Partners last year signed an initial agreement to provide research services to Xenon.

In the year ended Dec. 31, Discovery Partners lost $1.7 million, or 7 cents a share, on revenue of $10.9 million.

-John Seward; Dow Jones Newswires; 201-938-5400
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News